Peltopepimut- S

The companies will focus on research for metabolic and infectious diseases. Credit: Orawan Pattarawimonchai/Shutterstock. Evotec and Pfizer have entered a multi-year partnership that will focus initially on early discovery research. As part of the master research collaboration and option and licence agreement, the two companies will focus on research for metabolic and infectious diseases. Evotec plans to undertake research activities at its facilities in France, including the advanced Campus Curie research site in Toulouse. The site is equipped with high throughput screening capacity, in vitro and in vivo biology, metabolomics and proteomics. Evotec chief business officer Dr Matthias Evers stated: “We are honoured to collaborate with Pfizer to research potential new first-in-class therapeutic approaches. See Also: Dupixent “addresses current gap” in COPD biologics landscape Peltopepimut-s by ISA Pharmaceuticals for Cervical Cancer: Likelihood of Approval “Focusing on diseases with severe unmet medical needs and highly innovative therapeutic approaches, we look forward to supporting our partners at Pfizer with integrated R&D [research and development] activities.” Evotec will benefit from research support funding from Pfizer and may receive potential milestones and royalty payments contingent on the success of the programmes. Pfizer France vice-president and medical lead Dr Luca Mollo stated: “We are thrilled to collaborate with Evotec to conduct discovery research that may help unlock new approaches to treating pervasive metabolic and infectious diseases that impact millions of patients worldwide. “France has developed a strong biopharmaceutical ecosystem, which is why we’re thrilled to collaborate with Evotec to build on our shared commitment to advancing scientific discovery for diseases with unmet need.” In April 2024, Evotec and Variant Bio teamed up to detect a treatment for ailments caused by fibrosis. The alliance will combine Variant Bio’s genomic discovery expertise and its VB-Inference platform with Evotec’s antifibrotic drug discovery capabilities.

Around 5.2 million adults in the UK have moderate to severe atopic dermatitis. Image credit: Shutterstock / Kmpzzz. England’s National Institute for Health and Care Excellence ( Nice ) has recommended Almirall ’s Ebglyss (lebrikizumab) for patients with moderate to severe atopic dermatitis, giving NHS patients another biological therapy option. In line with NICE guidelines, the NHS will now have 90 days to make the treatment available to patients. Patients over 12 years of age who have not responded to or are not able to take systemic immunosuppressants will be eligible for the therapy, as per a 10 July press release. Monoclonal antibody Ebgylss will join Sanofi / Regeneron’s Dupixent (dupilumab) and Leo Pharma ’s Adbry (tralokinumab) as interleukin-targeting options for treating the skin condition. The Janus kinase (JAK) inhibitors Cibinqo (abrocitinib), Olumiant (baricitinib), and Rinvoq (upadacitinib) developed by Pfizer , Eli Lilly, and AbbVie , respectively, are also recommended by NICE. Atopic dermatitis, also known as atopic eczema, is an inflammatory skin condition characterised by intense itching. It has an estimated prevalence of up to 4.4% among adults in the EU. In the UK alone, around 5.2 million adults have moderate to severe atopic dermatitis. See Also: Dupixent “addresses current gap” in COPD biologics landscape Peltopepimut-s by ISA Pharmaceuticals for Cervical Cancer: Likelihood of Approval Ebglyss, which was approved in Europe in October 2023, and then two months later in the UK, works by inhibiting interleukin-13 (IL-13) signalling. IL-13 pathways play an important role in inflammation, driving the type-2 inflammatory loop in the skin. Adbry similarly targets IL-13 while Dupixent inhibits IL-13 and IL-4. The National Eczema Society’s chief executive Andrew Proctor said: “It’s important we have a range of treatment options, so patients have the chance to access a treatment that works well for them.” Almirall licensed the rights to develop and commercialise Ebglyss in dermatology indications, including atopic dermatitis, in Europe from Dermira in 2019. Dermira was then acquired by Eli Lilly, the latter retaining drug rights in the US and the rest of the world. Ebglyss is forecast to reach blockbuster status by 2026, according to GlobalData’s Pharma Intelligence Centre. By 2030, the drug is predicted to generate nearly $3.4bn in global sales. GlobalData is the parent company of Pharmaceutical Technology. Amid Sanofi and Regeneron’s Dupixent dominance , Johnson & Johnson (J&J) made a play for the atopic dermatitis space earlier this year when it spent $1.25bn to acquire Numab Therapeutics’ antibody NM26 in May.